130 related articles for article (PubMed ID: 9801931)
1. A significant relationship between plasminogen activator inhibitor type-1 and lipoprotein(a) in non-insulin-dependent diabetes mellitus without complications.
Testa R; Bonfigli AR; Pieri C; Marra M; Sirolla C; Manfrini S; Testa I
Int J Clin Lab Res; 1998; 28(3):187-91. PubMed ID: 9801931
[TBL] [Abstract][Full Text] [Related]
2. A strong inverse relationship between PAI-1 and Lp(a) in hypertensive Type 2 diabetic patients.
Testa R; Bonfigli AR; Sirolla C; Pieri C; Marra M; Antonicelli R; Manfrini S; Compagnucci P; Testa I
Diabetes Nutr Metab; 1999 Dec; 12(6):400-6. PubMed ID: 10782561
[TBL] [Abstract][Full Text] [Related]
3. Fibronectin and lipoprotein(a) are inversely related to plasminogen activator inhibitor type-1 levels in Type 2 diabetic patients without complications.
Testa R; Bonfigli AR; Sirolla C; De Grazia G; Compagnucci P; Manfrini S; Fumelli D; Testa I
Diabetes Nutr Metab; 2000 Oct; 13(5):269-75. PubMed ID: 11105969
[TBL] [Abstract][Full Text] [Related]
4. Relationship between plasminogen activator inhibitor type-1 plasma levels and the lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus.
Testa R; Bonfigli AR; Piantanelli L; Manfrini S; Testa I; Gregorio F
Diabetes Res Clin Pract; 1996 Jul; 33(2):111-8. PubMed ID: 8879966
[TBL] [Abstract][Full Text] [Related]
5. Lipoprotein(a), tissue plasminogen activator and plasminogen activator inhibitor 1 levels in hyperlipidaemic patients in Kuwait.
Akanji AO; Abdullah A; Tahzeeb S
Eur J Clin Invest; 1997 May; 27(5):380-6. PubMed ID: 9179544
[TBL] [Abstract][Full Text] [Related]
6. Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels.
Gürlek A; Bayraktar M; Kirazli S
Diabetes Care; 2000 Jan; 23(1):88-92. PubMed ID: 10857975
[TBL] [Abstract][Full Text] [Related]
7. The effect of obesity on fibrinolytic activity and plasma lipoprotein (a) levels in patients with type 2 diabetes mellitus in Korea.
Park YS; Park S; Park KS; Kim SY; Lee HK; Koh CS; Min HK; Kim JQ
Diabetes Res Clin Pract; 1994 May; 24(1):25-31. PubMed ID: 7924883
[TBL] [Abstract][Full Text] [Related]
8. Hypofibrinolysis associated with vasculopathy in non insulin dependent diabetes mellitus.
García Frade LJ; de la Calle H; Torrado MC; Lara JI; Cuellar L; García Avello A
Thromb Res; 1990 Jul; 59(1):51-9. PubMed ID: 2119076
[TBL] [Abstract][Full Text] [Related]
9. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus.
Carmassi F; Morale M; Puccetti R; De Negri F; Monzani F; Navalesi R; Mariani G
Thromb Res; 1992 Sep; 67(6):643-54. PubMed ID: 1440530
[TBL] [Abstract][Full Text] [Related]
10. Low order correlations of lipoprotein(a) with other blood lipids and with coagulation and fibrinolysis parameters in hypertensive and diabetic patients.
Donders SH; Lustermans FA; van Wersch JW
Blood Coagul Fibrinolysis; 1992 Jun; 3(3):249-56. PubMed ID: 1386533
[TBL] [Abstract][Full Text] [Related]
11. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus.
Auwerx J; Bouillon R; Collen D; Geboers J
Arteriosclerosis; 1988; 8(1):68-72. PubMed ID: 2449156
[TBL] [Abstract][Full Text] [Related]
12. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Kruszynska YT; Yu JG; Olefsky JM; Sobel BE
Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
[TBL] [Abstract][Full Text] [Related]
13. Markers of fibrinolysis may predict development of lower extremity arterial disease in patients with diabetes: A longitudinal prospective cohort study with 10 years of follow-up.
Rautio A; Boman K; Eriksson JW; Svensson MK
Diab Vasc Dis Res; 2016 May; 13(3):183-91. PubMed ID: 26818227
[TBL] [Abstract][Full Text] [Related]
14. The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients.
Vukovich T; Proidl S; Knöbl P; Teufelsbauer H; Schnack C; Schernthaner G
Thromb Haemost; 1992 Sep; 68(3):253-6. PubMed ID: 1440487
[TBL] [Abstract][Full Text] [Related]
15. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients.
Lindgren A; Lindoff C; Norrving B; Astedt B; Johansson BB
Stroke; 1996 Jun; 27(6):1066-71. PubMed ID: 8650716
[TBL] [Abstract][Full Text] [Related]
16. Hypercoagulability and high lipoprotein(a) levels in patients with type II diabetes mellitus.
Morishita E; Asakura H; Jokaji H; Saito M; Uotani C; Kumabashiri I; Yamazaki M; Aoshima K; Hashimoto T; Matsuda T
Atherosclerosis; 1996 Feb; 120(1-2):7-14. PubMed ID: 8645373
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
Petersen KR
Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
[TBL] [Abstract][Full Text] [Related]
18. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients--relationship with plasma insulin.
Juhan-Vague I; Roul C; Alessi MC; Ardissone JP; Heim M; Vague P
Thromb Haemost; 1989 Jun; 61(3):370-3. PubMed ID: 2678583
[TBL] [Abstract][Full Text] [Related]
19. [Fibrinolytic system in patients with myocardial infarction and other coronary disease risk factors].
Moreno JA; Gálvez MM; Cornudella R; Angós JA; Romero MS; Gutiérrez M
Sangre (Barc); 1994 Apr; 39(2):111-6. PubMed ID: 8059288
[TBL] [Abstract][Full Text] [Related]
20. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1.
Aso Y; Matsumoto S; Fujiwara Y; Tayama K; Inukai T; Takemura Y
Metabolism; 2002 Apr; 51(4):471-6. PubMed ID: 11912556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
